ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.505,79
-0,51%
S&P 500
5.631,22
0,28%
Dow Jones
40.211,72
0,53%
Euro vs US Dollar
1,08998
0,00%
Bitcoin
63.664,38
-1,83%
Registration Strip Icon for charts Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. AstraZeneca PLC (AZN)

  7. AstraZeneca PLC (AZN) News

AZN

AstraZeneca (AZN)

AstraZeneca PLC
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:AZN
DatumZeitQuelleÜberschriftSymbolFirma
20/11/202312h25IH Market NewsMonday’s Wall Street Highlights: GM, Microsoft, Citigroup, Amazon, and moreNASDAQ:AZNAstraZeneca PLC
20/11/202309h41Dow Jones NewsAstraZeneca Launches Health-Tech Business Evinova -- UpdateNASDAQ:AZNAstraZeneca PLC
20/11/202309h02Dow Jones NewsAstraZeneca Launches Health-Tech Business Evinova to Support Clinical StudiesNASDAQ:AZNAstraZeneca PLC
17/11/202313h00Business WireTRUQAP™ (capivasertib) plus fulvestrant approved in the US for patients with advanced HR-positive breast cancerNASDAQ:AZNAstraZeneca PLC
17/11/202312h36Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:AZNAstraZeneca PLC
16/11/202317h16Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:AZNAstraZeneca PLC
14/11/202312h35IH Market NewsTuesday’s Wall Street Highlights: Teck Resources, Starbucks, Nvidia, Fisker, Home Depot, and moreNASDAQ:AZNAstraZeneca PLC
09/11/202316h05Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:AZNAstraZeneca PLC
09/11/202316h01Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:AZNAstraZeneca PLC
09/11/202315h57Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:AZNAstraZeneca PLC
09/11/202315h49Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:AZNAstraZeneca PLC
09/11/202313h03Dow Jones NewsTrending: AstraZeneca Hikes Forecasts and Makes a $2 Billion Licensing DealNASDAQ:AZNAstraZeneca PLC
09/11/202313h02IH Market NewsThursday’s Wall Street Highlights: Nvidia, Duolingo, Disney, Virgin Galactic, Applovin, and moreNASDAQ:AZNAstraZeneca PLC
09/11/202313h00Business WireIMFINZI® (durvalumab) plus bevacizumab met primary endpoint for progression-free survival in liver cancer eligible for embolization in EMERALD-1 Phase III trialNASDAQ:AZNAstraZeneca PLC
09/11/202309h57Dow Jones NewsAstraZeneca Shares Rise After Guidance IncreaseNASDAQ:AZNAstraZeneca PLC
09/11/202309h16Dow Jones NewsAstraZeneca Agrees on Licensing Deal for Obesity TreatmentNASDAQ:AZNAstraZeneca PLC
09/11/202309h03Dow Jones NewsAstraZeneca Raises Core EPS Guidance Despite Profit Miss -- UpdateNASDAQ:AZNAstraZeneca PLC
09/11/202308h50Dow Jones NewsAstraZeneca Raises Core EPS Guidance Despite Profit MissNASDAQ:AZNAstraZeneca PLC
08/11/202313h00Business WireAstraZeneca to leverage its global industrial-scale manufacturing and digital capabilities to boost US renewable natural gas productivityNASDAQ:AZNAstraZeneca PLC
03/11/202316h30Business WireZibotentan/dapagliflozin combination demonstrated significant albuminuria reduction in patients with chronic kidney disease and proteinuria in ZENITH-CKD Phase IIb trialNASDAQ:AZNAstraZeneca PLC
01/11/202312h52Dow Jones NewsCellectis Shares Soar Premarket on AstraZeneca DealNASDAQ:AZNAstraZeneca PLC
01/11/202312h51Dow Jones NewsCellectis Shares Soar Premarket on AstraZeneca DealNASDAQ:AZNAstraZeneca PLC
01/11/202312h51Dow Jones NewsCellectis Shares Soar Premarket on AstraZeneca DealNASDAQ:AZNAstraZeneca PLC
01/11/202312h00PR Newswire (Canada)Health Canada approves Ultomiris for adults with neuromyelitis optica spectrum disorder (NMOSD)NASDAQ:AZNAstraZeneca PLC
01/11/202312h00PR Newswire (Canada)Santé Canada approuve ULTOMIRIS pour les adultes atteints de troubles du spectre de la neuromyélite optique (NMOSD)NASDAQ:AZNAstraZeneca PLC
01/11/202309h17Dow Jones NewsAstraZeneca to Invest $245 Million in Deal With CellectisNASDAQ:AZNAstraZeneca PLC
30/10/202313h45InvestorsHub NewsWireCan Diabetes, Weight-Loss Drugs Get Even Better?NASDAQ:AZNAstraZeneca PLC
24/10/202313h00Business WireUS Food and Drug Administration accepts for review AstraZeneca’s Supplemental Biologics License Application for self-administration of FLUMIST® QUADRIVALENT (Influenza Vaccine Live, Intranasal)NASDAQ:AZNAstraZeneca PLC
24/10/202313h00PR Newswire (Canada)Alexion, AstraZeneca Rare Disease, conclut une lettre d'intention (LI) avec l'Alliance pancanadienne pharmaceutique (APP) pour Ultomiris pour le traitement des patients atteints d'hémoglobinurie paroxystique nocturne ou du syndrome hémolytique et urémiqNASDAQ:AZNAstraZeneca PLC
24/10/202313h00PR Newswire (Canada)Alexion, AstraZeneca Rare Disease, concludes Letter of Intent (LOI) with the pan-Canadian Pharmaceutical Alliance (pCPA) for Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria or atypical hemolytic uremic syndromeNASDAQ:AZNAstraZeneca PLC
 Showing the most relevant articles for your search:NASDAQ:AZN

Kürzlich von Ihnen besucht

DBI
TDXP
Tec DAX
TG
MBG
MercedesBenz
TG
DBK
Deutsche Bank
TG
RHM
Rheinmetall
TG
NOV
Novo Nordisk
NASDAQ
TSLA
Tesla
NASDAQ
AMZN
Amazon.com
CCOM
SILVER
SILVER
TG
CBK
Commerzbank
USOTC
BNPQY
BNP Paribas (QX)
AMEX
SPY
SPDR S&P 500
TG
432
Arbor Metals
NYSE
XOM
Exxon Mobil
AMEX
XLV
Health Care Select Sector
TG
ALV
Allianz
CCOM
US500
US 500
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten